You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Clinical outcomes for some of the most extensively researched bone grafting material on the market.
SEE OUTCOMESInfuseTM Bone Graft induces new bone tissue at the site of implantation. The bone formation process develops from the outside of the implant towards the center until the entire device is replaced by trabecular bone.
LEARN ABOUT INFUSE BONE GRAFTMasterGraft™ bone graft products are osteoconductive, resorbable scaffolds that extend autograft and facilitate the delivery — and maintain the viability — of the patient’s own cells.1
LEARN ABOUT MASTERGRAFT GRANULESGrafton™ demineralized bone matrix (DBM) is the most utilized and scientifically studied DBM brand.*
LEARN ABOUT GRAFTON DBMINDICATIONS, CONTRAINDICATIONS, WARNINGS, AND PRECAUTION FOR INFUSE BONE GRAFT FOR CERTAIN ORAL MAXILLOFACIAL AND DENTAL REGENERATIVE USES
INFUSE® Bone Graft is indicated as an alternative to autogenous bone graft for sinus augmentations, and for localized alveolar ridge augmentations for defects associated with extraction sockets.
The INFUSE® Bone Graft consists of two components–recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) placed on an absorbable collagen sponge (ACS). These components must be used as a system for the prescribed indication. The bone morphogenetic protein solution component must not be used without the carrier/scaffold component or with a carrier/scaffold component different from the one described in the package insert.
INFUSE® Bone Graft is contraindicated for patients with a known hypersensitivity to recombinant human Bone Morphogenetic Protein-2, bovine Type I collagen or to other components of the formulation and should not be used in the vicinity of a resected or extant tumor, in patients with any active malignancy or consumers undergoing treatment for a malignancy, in pregnant women, or patients with an active infection at the operative site.
There are no adequate and well-controlled studies in human pregnant women. In an experimental rabbit study, rhBMP-2 has been shown to elicit antibodies that are capable of crossing the placenta. Women of childbearing potential should be warned by their surgeon of potential risk to a fetus and informed of other possible dental treatments. The safety and effectiveness of this device has not been established in nursing mothers. Women of childbearing potential should be advised to not become pregnant for one year following treatment with this device.
INFUSE® Bone Graft has not been studied in patients who are skeletally immature (<18 years of age or no radiographic evidence of epiphyseal closure).
Please see the package insert for the complete list of indications, warnings, precautions, adverse events, clinical results, and other important medical information.
MASTERGRAFT: CONTRAINDICATIONS
This product is not intended to provide structural support during the healing process, therefore, Mastergraft Granules is contraindicated where the device is intended as structural support in the skeletal system.
Conditions representing relative contraindications include:
MASTERGRAFT: POTENTIAL ADVERSE EVENTS
A listing of potential adverse events includes, but is not limited to:
GRAFTON: CONTRAINDICATIONS
The following are contraindications for the use of GRAFTON™ DBM and GRAFTON PLUS™ DBM:
GRAFTON: CAUTION
This allograft may contain trace amounts of antibiotics (gentamicin), surfactant, and other processing solutions. Caution should be exercised if the patient is allergic to these antibiotics or chemicals. GRAFTON PLUS™ DBM Paste contains starch. Therefore, caution should be exercised in using GRAFTON PLUS™ DBM Paste in a patient with a starch allergy and/or amylase deficiency.
Please see the package insert for the complete list of indications, warnings, precautions, adverse events, clinical results and other important medical information
Kim HJ, et al. Transplanted xenogenic bone marrow stem cells survive and generate new bone formation in the posterolateral lumbar spine of non-immunosuppressed rabbits, Eur Spine J 2008, 17:1515–1521
Based on Pub-Med search on 8/26/14 with keywords Grafton, DBX and Osteosponge.